Drugs / Nacresertib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07649954 | Jun → Sep 2026 expected | — | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07600762 | Apr → Jun 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT07566130 | Apr 2025 → May 2026 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nacresertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07649954 ↗ |
| Modality | Small molecule | — CHEMBL6068062 ↗ |
| Route | Oral | “Oral” NCT07566130 ↗ |